Page last updated: 2024-09-03

ak 2123 and Oropharyngeal Neoplasms

ak 2123 has been researched along with Oropharyngeal Neoplasms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chatterjee, N; Huilgol, NG; Mehta, AR1

Trials

1 trial(s) available for ak 2123 and Oropharyngeal Neoplasms

ArticleYear
An overview of the initial experience with AK-2123 as a hypoxic cell sensitizer with radiation in the treatment of advanced head and neck cancers.
    International journal of radiation oncology, biology, physics, 1996, Mar-15, Volume: 34, Issue:5

    Topics: Adult; Aged; Humans; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Radiation-Sensitizing Agents; Remission Induction; Triazoles

1996